The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy
• Resistance to crizotinib, the first ALK inhibitor for NSCLC, inevitably develops. • Next-generation ALK inhibitors are already approved and in development. • Ceritinib potently overcomes many crizotinib resistance mutations in vitro. • Ceritinib is effective in ALK-inhibitor–pre-treated and –naïve...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Mok, Tony S.K. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Using regression analysis to predict the future energy consumption of a supermarket in the UK - Braun, M.R. ELSEVIER, 2014, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:55 ; year:2017 ; pages:181-189 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ctrv.2017.03.006 |
|---|
| Katalog-ID: |
ELV035863692 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV035863692 | ||
| 003 | DE-627 | ||
| 005 | 20230624024231.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ctrv.2017.03.006 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017010000007.pica |
| 035 | |a (DE-627)ELV035863692 | ||
| 035 | |a (ELSEVIER)S0305-7372(17)30043-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 620 |q VZ |
| 082 | 0 | 4 | |a 150 |a 300 |q VZ |
| 084 | |a 77.52 |2 bkl | ||
| 100 | 1 | |a Mok, Tony S.K. |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy |
| 264 | 1 | |c 2017 | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Resistance to crizotinib, the first ALK inhibitor for NSCLC, inevitably develops. • Next-generation ALK inhibitors are already approved and in development. • Ceritinib potently overcomes many crizotinib resistance mutations in vitro. • Ceritinib is effective in ALK-inhibitor–pre-treated and –naïve NSCLC patients. • GI toxicity with ceritinib is manageable with dose interruptions/reductions. | ||
| 650 | 7 | |a Neoplasm |2 Elsevier | |
| 650 | 7 | |a Carcinoma |2 Elsevier | |
| 650 | 7 | |a Non–small-cell lung |2 Elsevier | |
| 650 | 7 | |a Drug resistance |2 Elsevier | |
| 650 | 7 | |a Anaplastic lymphoma kinase |2 Elsevier | |
| 650 | 7 | |a Ceritinib |2 Elsevier | |
| 700 | 1 | |a Crino, Lucio |4 oth | |
| 700 | 1 | |a Felip, Enriqueta |4 oth | |
| 700 | 1 | |a Salgia, Ravi |4 oth | |
| 700 | 1 | |a De Pas, Tommaso |4 oth | |
| 700 | 1 | |a Tan, Daniel S.W. |4 oth | |
| 700 | 1 | |a Chow, Laura Q.M. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Braun, M.R. ELSEVIER |t Using regression analysis to predict the future energy consumption of a supermarket in the UK |d 2014 |g Amsterdam [u.a.] |w (DE-627)ELV01225004X |
| 773 | 1 | 8 | |g volume:55 |g year:2017 |g pages:181-189 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ctrv.2017.03.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 77.52 |j Differentielle Psychologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 55 |j 2017 |h 181-189 |g 9 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
t s m ts tsm |
|---|---|
| matchkey_str |
moktonyskcrinoluciofelipenriquetasalgiar:2017----:haclrtdahfeiiitasaigrciiadvlpe |
| hierarchy_sort_str |
2017 |
| bklnumber |
77.52 |
| publishDate |
2017 |
| allfields |
10.1016/j.ctrv.2017.03.006 doi GBVA2017010000007.pica (DE-627)ELV035863692 (ELSEVIER)S0305-7372(17)30043-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Mok, Tony S.K. verfasserin aut The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy 2017 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Resistance to crizotinib, the first ALK inhibitor for NSCLC, inevitably develops. • Next-generation ALK inhibitors are already approved and in development. • Ceritinib potently overcomes many crizotinib resistance mutations in vitro. • Ceritinib is effective in ALK-inhibitor–pre-treated and –naïve NSCLC patients. • GI toxicity with ceritinib is manageable with dose interruptions/reductions. Neoplasm Elsevier Carcinoma Elsevier Non–small-cell lung Elsevier Drug resistance Elsevier Anaplastic lymphoma kinase Elsevier Ceritinib Elsevier Crino, Lucio oth Felip, Enriqueta oth Salgia, Ravi oth De Pas, Tommaso oth Tan, Daniel S.W. oth Chow, Laura Q.M. oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:55 year:2017 pages:181-189 extent:9 https://doi.org/10.1016/j.ctrv.2017.03.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 55 2017 181-189 9 045F 610 |
| spelling |
10.1016/j.ctrv.2017.03.006 doi GBVA2017010000007.pica (DE-627)ELV035863692 (ELSEVIER)S0305-7372(17)30043-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Mok, Tony S.K. verfasserin aut The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy 2017 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Resistance to crizotinib, the first ALK inhibitor for NSCLC, inevitably develops. • Next-generation ALK inhibitors are already approved and in development. • Ceritinib potently overcomes many crizotinib resistance mutations in vitro. • Ceritinib is effective in ALK-inhibitor–pre-treated and –naïve NSCLC patients. • GI toxicity with ceritinib is manageable with dose interruptions/reductions. Neoplasm Elsevier Carcinoma Elsevier Non–small-cell lung Elsevier Drug resistance Elsevier Anaplastic lymphoma kinase Elsevier Ceritinib Elsevier Crino, Lucio oth Felip, Enriqueta oth Salgia, Ravi oth De Pas, Tommaso oth Tan, Daniel S.W. oth Chow, Laura Q.M. oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:55 year:2017 pages:181-189 extent:9 https://doi.org/10.1016/j.ctrv.2017.03.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 55 2017 181-189 9 045F 610 |
| allfields_unstemmed |
10.1016/j.ctrv.2017.03.006 doi GBVA2017010000007.pica (DE-627)ELV035863692 (ELSEVIER)S0305-7372(17)30043-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Mok, Tony S.K. verfasserin aut The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy 2017 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Resistance to crizotinib, the first ALK inhibitor for NSCLC, inevitably develops. • Next-generation ALK inhibitors are already approved and in development. • Ceritinib potently overcomes many crizotinib resistance mutations in vitro. • Ceritinib is effective in ALK-inhibitor–pre-treated and –naïve NSCLC patients. • GI toxicity with ceritinib is manageable with dose interruptions/reductions. Neoplasm Elsevier Carcinoma Elsevier Non–small-cell lung Elsevier Drug resistance Elsevier Anaplastic lymphoma kinase Elsevier Ceritinib Elsevier Crino, Lucio oth Felip, Enriqueta oth Salgia, Ravi oth De Pas, Tommaso oth Tan, Daniel S.W. oth Chow, Laura Q.M. oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:55 year:2017 pages:181-189 extent:9 https://doi.org/10.1016/j.ctrv.2017.03.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 55 2017 181-189 9 045F 610 |
| allfieldsGer |
10.1016/j.ctrv.2017.03.006 doi GBVA2017010000007.pica (DE-627)ELV035863692 (ELSEVIER)S0305-7372(17)30043-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Mok, Tony S.K. verfasserin aut The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy 2017 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Resistance to crizotinib, the first ALK inhibitor for NSCLC, inevitably develops. • Next-generation ALK inhibitors are already approved and in development. • Ceritinib potently overcomes many crizotinib resistance mutations in vitro. • Ceritinib is effective in ALK-inhibitor–pre-treated and –naïve NSCLC patients. • GI toxicity with ceritinib is manageable with dose interruptions/reductions. Neoplasm Elsevier Carcinoma Elsevier Non–small-cell lung Elsevier Drug resistance Elsevier Anaplastic lymphoma kinase Elsevier Ceritinib Elsevier Crino, Lucio oth Felip, Enriqueta oth Salgia, Ravi oth De Pas, Tommaso oth Tan, Daniel S.W. oth Chow, Laura Q.M. oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:55 year:2017 pages:181-189 extent:9 https://doi.org/10.1016/j.ctrv.2017.03.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 55 2017 181-189 9 045F 610 |
| allfieldsSound |
10.1016/j.ctrv.2017.03.006 doi GBVA2017010000007.pica (DE-627)ELV035863692 (ELSEVIER)S0305-7372(17)30043-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl Mok, Tony S.K. verfasserin aut The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy 2017 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Resistance to crizotinib, the first ALK inhibitor for NSCLC, inevitably develops. • Next-generation ALK inhibitors are already approved and in development. • Ceritinib potently overcomes many crizotinib resistance mutations in vitro. • Ceritinib is effective in ALK-inhibitor–pre-treated and –naïve NSCLC patients. • GI toxicity with ceritinib is manageable with dose interruptions/reductions. Neoplasm Elsevier Carcinoma Elsevier Non–small-cell lung Elsevier Drug resistance Elsevier Anaplastic lymphoma kinase Elsevier Ceritinib Elsevier Crino, Lucio oth Felip, Enriqueta oth Salgia, Ravi oth De Pas, Tommaso oth Tan, Daniel S.W. oth Chow, Laura Q.M. oth Enthalten in Elsevier Braun, M.R. ELSEVIER Using regression analysis to predict the future energy consumption of a supermarket in the UK 2014 Amsterdam [u.a.] (DE-627)ELV01225004X volume:55 year:2017 pages:181-189 extent:9 https://doi.org/10.1016/j.ctrv.2017.03.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 77.52 Differentielle Psychologie VZ AR 55 2017 181-189 9 045F 610 |
| language |
English |
| source |
Enthalten in Using regression analysis to predict the future energy consumption of a supermarket in the UK Amsterdam [u.a.] volume:55 year:2017 pages:181-189 extent:9 |
| sourceStr |
Enthalten in Using regression analysis to predict the future energy consumption of a supermarket in the UK Amsterdam [u.a.] volume:55 year:2017 pages:181-189 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Differentielle Psychologie |
| institution |
findex.gbv.de |
| topic_facet |
Neoplasm Carcinoma Non–small-cell lung Drug resistance Anaplastic lymphoma kinase Ceritinib |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| authorswithroles_txt_mv |
Mok, Tony S.K. @@aut@@ Crino, Lucio @@oth@@ Felip, Enriqueta @@oth@@ Salgia, Ravi @@oth@@ De Pas, Tommaso @@oth@@ Tan, Daniel S.W. @@oth@@ Chow, Laura Q.M. @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV01225004X |
| dewey-sort |
3610 |
| id |
ELV035863692 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035863692</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624024231.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ctrv.2017.03.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017010000007.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035863692</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0305-7372(17)30043-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">620</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="a">300</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">77.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Mok, Tony S.K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Resistance to crizotinib, the first ALK inhibitor for NSCLC, inevitably develops. • Next-generation ALK inhibitors are already approved and in development. • Ceritinib potently overcomes many crizotinib resistance mutations in vitro. • Ceritinib is effective in ALK-inhibitor–pre-treated and –naïve NSCLC patients. • GI toxicity with ceritinib is manageable with dose interruptions/reductions.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neoplasm</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Carcinoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non–small-cell lung</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug resistance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anaplastic lymphoma kinase</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ceritinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Crino, Lucio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Felip, Enriqueta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Salgia, Ravi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Pas, Tommaso</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tan, Daniel S.W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chow, Laura Q.M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Braun, M.R. ELSEVIER</subfield><subfield code="t">Using regression analysis to predict the future energy consumption of a supermarket in the UK</subfield><subfield code="d">2014</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV01225004X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:55</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:181-189</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ctrv.2017.03.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">77.52</subfield><subfield code="j">Differentielle Psychologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">55</subfield><subfield code="j">2017</subfield><subfield code="h">181-189</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Mok, Tony S.K. |
| spellingShingle |
Mok, Tony S.K. ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Neoplasm Elsevier Carcinoma Elsevier Non–small-cell lung Elsevier Drug resistance Elsevier Anaplastic lymphoma kinase Elsevier Ceritinib The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy |
| authorStr |
Mok, Tony S.K. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV01225004X |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 620 - Engineering & allied operations 150 - Psychology 300 - Social sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy Neoplasm Elsevier Carcinoma Elsevier Non–small-cell lung Elsevier Drug resistance Elsevier Anaplastic lymphoma kinase Elsevier Ceritinib Elsevier |
| topic |
ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Neoplasm Elsevier Carcinoma Elsevier Non–small-cell lung Elsevier Drug resistance Elsevier Anaplastic lymphoma kinase Elsevier Ceritinib |
| topic_unstemmed |
ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Neoplasm Elsevier Carcinoma Elsevier Non–small-cell lung Elsevier Drug resistance Elsevier Anaplastic lymphoma kinase Elsevier Ceritinib |
| topic_browse |
ddc 610 ddc 620 ddc 150 bkl 77.52 Elsevier Neoplasm Elsevier Carcinoma Elsevier Non–small-cell lung Elsevier Drug resistance Elsevier Anaplastic lymphoma kinase Elsevier Ceritinib |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
l c lc e f ef r s rs p t d pt ptd d s t ds dst l q c lq lqc |
| hierarchy_parent_title |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| hierarchy_parent_id |
ELV01225004X |
| dewey-tens |
610 - Medicine & health 620 - Engineering 150 - Psychology 300 - Social sciences, sociology & anthropology |
| hierarchy_top_title |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV01225004X |
| title |
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy |
| ctrlnum |
(DE-627)ELV035863692 (ELSEVIER)S0305-7372(17)30043-9 |
| title_full |
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy |
| author_sort |
Mok, Tony S.K. |
| journal |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| journalStr |
Using regression analysis to predict the future energy consumption of a supermarket in the UK |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 100 - Philosophy & psychology 300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
181 |
| author_browse |
Mok, Tony S.K. |
| container_volume |
55 |
| physical |
9 |
| class |
610 610 DE-600 620 VZ 150 300 VZ 77.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Mok, Tony S.K. |
| doi_str_mv |
10.1016/j.ctrv.2017.03.006 |
| dewey-full |
610 620 150 300 |
| title_sort |
accelerated path of ceritinib: translating pre-clinical development into clinical efficacy |
| title_auth |
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy |
| abstract |
• Resistance to crizotinib, the first ALK inhibitor for NSCLC, inevitably develops. • Next-generation ALK inhibitors are already approved and in development. • Ceritinib potently overcomes many crizotinib resistance mutations in vitro. • Ceritinib is effective in ALK-inhibitor–pre-treated and –naïve NSCLC patients. • GI toxicity with ceritinib is manageable with dose interruptions/reductions. |
| abstractGer |
• Resistance to crizotinib, the first ALK inhibitor for NSCLC, inevitably develops. • Next-generation ALK inhibitors are already approved and in development. • Ceritinib potently overcomes many crizotinib resistance mutations in vitro. • Ceritinib is effective in ALK-inhibitor–pre-treated and –naïve NSCLC patients. • GI toxicity with ceritinib is manageable with dose interruptions/reductions. |
| abstract_unstemmed |
• Resistance to crizotinib, the first ALK inhibitor for NSCLC, inevitably develops. • Next-generation ALK inhibitors are already approved and in development. • Ceritinib potently overcomes many crizotinib resistance mutations in vitro. • Ceritinib is effective in ALK-inhibitor–pre-treated and –naïve NSCLC patients. • GI toxicity with ceritinib is manageable with dose interruptions/reductions. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy |
| url |
https://doi.org/10.1016/j.ctrv.2017.03.006 |
| remote_bool |
true |
| author2 |
Crino, Lucio Felip, Enriqueta Salgia, Ravi De Pas, Tommaso Tan, Daniel S.W. Chow, Laura Q.M. |
| author2Str |
Crino, Lucio Felip, Enriqueta Salgia, Ravi De Pas, Tommaso Tan, Daniel S.W. Chow, Laura Q.M. |
| ppnlink |
ELV01225004X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| doi_str |
10.1016/j.ctrv.2017.03.006 |
| up_date |
2024-07-06T18:41:04.387Z |
| _version_ |
1803856132847960064 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035863692</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624024231.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ctrv.2017.03.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017010000007.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035863692</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0305-7372(17)30043-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">620</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="a">300</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">77.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Mok, Tony S.K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Resistance to crizotinib, the first ALK inhibitor for NSCLC, inevitably develops. • Next-generation ALK inhibitors are already approved and in development. • Ceritinib potently overcomes many crizotinib resistance mutations in vitro. • Ceritinib is effective in ALK-inhibitor–pre-treated and –naïve NSCLC patients. • GI toxicity with ceritinib is manageable with dose interruptions/reductions.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neoplasm</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Carcinoma</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non–small-cell lung</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug resistance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anaplastic lymphoma kinase</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ceritinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Crino, Lucio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Felip, Enriqueta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Salgia, Ravi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Pas, Tommaso</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tan, Daniel S.W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chow, Laura Q.M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Braun, M.R. ELSEVIER</subfield><subfield code="t">Using regression analysis to predict the future energy consumption of a supermarket in the UK</subfield><subfield code="d">2014</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV01225004X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:55</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:181-189</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ctrv.2017.03.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">77.52</subfield><subfield code="j">Differentielle Psychologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">55</subfield><subfield code="j">2017</subfield><subfield code="h">181-189</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3994913 |